By Susan Jeffrey, Contributing Writer, MedPage Today
November 7, 2026
The quest to harness the immune system to combat cardiovascular disease reached a sobering milestone this week at the American Heart Association (AHA) annual meeting in Chicago. The results of the ZEUS trial—a large-scale, global investigation into the monoclonal antibody ziltivekimab—have challenged the prevailing paradigm that systemic inflammation can be universally targeted to improve outcomes in high-risk patients. Despite achieving profound reductions in inflammatory markers, the therapy failed to move the needle on major cardiovascular events, leaving researchers to grapple with the complexities of disease progression and the "point of no return" in chronic pathology.
Main Facts: The ZEUS Trial Findings
The ZEUS trial was a global, double-blind, randomized, placebo-controlled study designed to test the efficacy of ziltivekimab, a monoclonal antibody that targets the interleukin-6 (IL-6) ligand. The study enrolled 6,376 patients who represented a "triple threat" of clinical vulnerability: established atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and persistent systemic inflammation, defined as a high-sensitivity C-reactive protein (hs-CRP) level exceeding 2 mg per liter.
Patients were randomized to receive either 15 mg of subcutaneous ziltivekimab or a placebo once a month. Over a median follow-up of 33 months, the primary composite endpoint—comprising death from cardiovascular causes, nonfatal myocardial infarction (MI), or nonfatal stroke—showed no significant difference between the two arms. Specifically, 561 patients (17.6%) in the ziltivekimab group experienced an event, compared to 565 patients (17.7%) in the placebo group (hazard ratio 0.99; 95% CI 0.88–1.11; P=0.84).
Secondary endpoints, including a four-point major adverse cardiovascular event (MACE) composite, hospitalization for unstable angina, and all-cause mortality, similarly failed to demonstrate a therapeutic benefit. While the drug proved highly effective at suppressing inflammation—resulting in a 76% placebo-adjusted reduction in free IL-6 and a 64% reduction in hs-CRP—this biochemical success did not translate into clinical improvement.
Chronology: From Genetic Theory to Clinical Reality
The journey toward the ZEUS trial results began years ago, bolstered by compelling data from Mendelian randomization studies. These genetic analyses suggested that the IL-6 pathway was not merely a byproduct of cardiovascular stress but a causal driver of the inflammatory cascade leading to plaque instability and rupture.
- Pre-2026: Researchers observed that genetic variations influencing IL-6 levels were strongly associated with cardiovascular risk, leading to the hypothesis that therapeutic inhibition of this pathway would replicate the protective effects seen in genetic models.
- July 2026: As the trial reached its conclusion, Novo Nordisk, the sponsor of the ZEUS study, released topline results indicating the trial had not met its primary endpoint. This early announcement set the stage for the detailed data presentation at the AHA meeting.
- November 2026: Dr. Paul M. Ridker, the study’s lead investigator, formally presented the full dataset at the AHA annual meeting in Chicago, with the findings published simultaneously in the New England Journal of Medicine.
This trajectory—from the excitement of genetic validation to the neutral outcome of a Phase III clinical trial—highlights the recurring challenge in modern medicine: the distinction between biological causality and therapeutic reversibility.
Supporting Data: Understanding the Population and Risks
A critical aspect of the ZEUS findings lies in the characteristics of the patient population. Compared to previous landmark studies like CANTOS (which used canakinumab), the ZEUS cohort was significantly sicker. ZEUS participants suffered from advanced CKD, higher rates of diabetes, and a greater prevalence of heart failure. Consequently, the all-cause mortality rate in the ZEUS trial was roughly double that observed in earlier anti-inflammatory studies.
The "Late-Stage" Hypothesis
Dr. Ridker suggested that the trial’s failure might be attributed to the timing of the intervention. "The horse may already have been out of the barn," he noted during his presentation. In patients with long-standing, multi-organ disease, the inflammatory processes may have already induced irreversible structural changes in the vasculature and myocardium. In this context, suppressing inflammatory markers like CRP and IL-6 may be "too little, too late" to alter the clinical trajectory.
Safety Considerations
The safety profile of ziltivekimab also warrants careful review. While serious adverse events were balanced between the treatment and placebo groups (54.6% vs. 54.8%), there were notable differences in specific areas. Serious infections were reported in 20.4% of the treatment arm compared to 17.9% in the placebo group, a statistically significant difference. Furthermore, the incidence of venous thromboembolism was higher in the ziltivekimab group (1.6% vs. 0.6%), suggesting that while IL-6 inhibition reduces inflammatory markers, it may also interfere with essential homeostatic immune functions.
Official Responses and Clinical Implications
The medical community has received the ZEUS results with a mixture of disappointment and scientific pragmatism. The consensus is that while the trial failed to prove the efficacy of this specific drug in this specific population, it remains a vital contribution to our understanding of vascular biology.
Perspective from the Podium
AHA discussant Dr. Priscilla Hsue of the University of California, San Francisco, emphasized that the trial’s neutral results should not be interpreted as a failure of the "inflammation hypothesis" in cardiovascular disease. Instead, she urged researchers to ask deeper questions: Was the strategy flawed by targeting the ligand rather than the receptor? Was the timing of the intervention too late?
"The take-home from this session should not be that inflammation doesn’t matter," Dr. Hsue stated. "Rather, the need for mechanistic studies and precise patient selection is more important in 2026 than ever."
Future Directions
The failure of ZEUS has not halted the broader investigation into inflammation. Dr. Ridker noted that while the HERMES trial (investigating ziltivekimab in heart failure with midrange or preserved ejection fraction) was halted for futility, other studies remain active. The ARTEMIS trial, which focuses on patients with acute coronary ischemia, is continuing, offering hope that the drug might find a successful niche in an earlier, more acute stage of disease.
Furthermore, the industry is shifting its gaze toward more upstream targets. The NLRP3 inflammasome, which sits at the top of the inflammatory hierarchy, is currently being targeted by several novel oral agents. By blocking the pathway before IL-1 and IL-6 are produced, researchers hope to achieve better clinical outcomes with a more favorable safety profile.
The Path Forward: Managing Residual Inflammatory Risk
Despite the ZEUS outcome, clinicians are not without tools to address residual inflammatory risk. Dr. Ridker emphasized that the foundational pillars of cardiovascular care remain essential. Diet, regular physical activity, and smoking cessation remain the most effective, non-pharmacological methods to lower systemic inflammation.
Furthermore, existing therapies have already demonstrated the ability to modulate the inflammatory environment:
- Statins: Known to have pleiotropic anti-inflammatory effects.
- Colchicine: Proven to reduce cardiovascular event rates in patients with stable coronary disease.
- GLP-1 Receptor Agonists: Increasingly recognized for their systemic anti-inflammatory benefits beyond their metabolic effects.
The "relevant question moving forward," as Dr. Ridker concluded, is not whether we should target inflammation, but rather which drugs should be used, when they should be administered, and—most importantly—in which patient populations they will provide the most benefit. The ZEUS trial serves as a definitive reminder that in the complex, long-term evolution of chronic disease, clinical success requires more than just changing a blood marker; it requires intervening at the right time, in the right way, for the right patient.
